Characteristic | Pramipexole ER | Pramipexole IR | Total |
---|---|---|---|
n=236 | n=239 | n=475 | |
Age, mean (±SD) years | 62.2(9.10) | 61.8(9.03) | 62.0(9.06) |
<65 | 140(59.8) | 146(61.1) | 286(60.5) |
≥65 | 94(40.2) | 93(38.9) | 187(39.5) |
Female sex, n (%) | 80(34.2) | 95(39.7) | 175(37.0) |
Body mass index, mean (±SD) kg/m 2 | 23.3(2.85) | 23.3(3.06) | 23.3(2.95) |
Hoehn and Yahr stage, n (%) | |||
On phase | |||
2-3 | 226(96.6) | 234(97.9) | 460(97.3) |
4-5 | 8(3.4) | 5(2.1) | 13(2.7) |
Off phase | |||
2-3 | 113(48.3) | 119(49.8) | 232(49.0) |
4-5 | 18(7.7) | 18(7.5) | 36(7.6) |
Missing | 103(44.0) | 102(42.7) | 205(43.3) |
UPDRS score, mean (±SD) | |||
II | 13.0(4.92) | 13.0(5.97) | 13.0(5.47) |
III | 31.7(12.09) | 32.1(12.78) | 31.9(12.43) |
II+III | 44.7(15.69) | 45.1(17.31) | 44.9(16.51) |
PD stage, n (%) | |||
Early | 122(52.1) | 133(55.6) | 255(53.9) |
Advanced | 112(47.9) | 106(44.4) | 218(46.1) |
Duration of disease, mean (±SD) years | 5.11(3.33) | 4.82(3.09) | 4.96(3.21) |
2 to <5, n (%) | 146(62.4) | 153(64.0) | 299(63.2) |
≥5, n (%) | 88(37.6) | 86(36.0) | 174(36.8) |
MMSE score, mean (±SD) | 28.4(1.61) | 28.4(1.44) | 28.4(1.52) |
ESS score, mean (±SD) | 5.0(3.81) | 5.4(4.13) | 5.2(3.97) |